Effects of the aminopeptidase P inhibitor apstatin on bradykinin-induced inositol 1,4,5-triphosphate in neonatal rat cardiomyocytes

被引:0
作者
Kudoh, A [1 ]
Kudoh, E
Katagai, H
Takazawa, T
机构
[1] Natl Hosp, Dept Anesthesiol, Hirosaki, Aomori 0368545, Japan
[2] Natl Hosp, Dept Pediat, Hirosaki, Aomori 0368545, Japan
关键词
aminopeptidase P; bradykinin; inositol 1,2,5-triphosphate; glucose uptake; angiotensin-converting enzyme inhibitors;
D O I
10.1097/00005344-200105000-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated the effect of apstatin (an aminopeptidase P inhibitor) on bradykinin-induced inositol 1,4,5-triphosphate (IP3) formation and glucose uptake in isolated neonatal rat cardiomyocytes. Apstatin enhanced bradykinin-induced IF, formation in a dose-dependent manner. We found that muM Hoe 140 (a bradykinin B-2-receptor antagonist) significantly decreased the potentiation of bradykinin-induced IP3 production by 5 muM apstatin from 781.8 +/- 67.2 to 127.4 +/- 33.0 pmol/mg protein; 5 muM apstatin increased bradykinin-induced glucose uptake from 197.0 +/- 25.5 to 297.3 +/- 64.0 pmol/h per milligram of protein. The stimulation of glucose uptake with apstatin was blocked to 132.5 +/- 26.2 pmol/h per milligram of protein by 1 muM Hoe 140. We conclude that apstatin stimulates bradykinin-induced IP3 formation and glucose uptake by preventing the degradation of bradykinin.
引用
收藏
页码:495 / 501
页数:7
相关论文
共 20 条
  • [11] Prechel MM, 1995, J PHARMACOL EXP THER, V275, P1136
  • [12] Attenuation of epinephrine-induced dysrhythmias by bradykinin: Role of nitric oxide and prostaglandins
    Rajani, V
    Hussain, Y
    Bolla, BS
    deGuzman, FQ
    Montiague, RR
    Igic, R
    Rabito, SF
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (3A) : A153 - A157
  • [13] RETT K, 1990, J CARDIOVASC PHARM, V15, pS57, DOI 10.1097/00005344-199015061-00011
  • [14] SADOSHIMA J, 1992, J BIOL CHEM, V267, P10551
  • [15] SCHOLKENS BA, 1991, J CARDIOVASC PHARM, V18, pS26
  • [16] SCHROR K, 1992, J CARDIOVASC PHAR S9, V20, P68
  • [17] Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme kininase II in the ischemic zone: Mediated by endogenous bradykinin?
    Shimada, Y
    Avkiran, M
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1996, 27 (03) : 428 - 438
  • [18] SIMMONS WH, J BIOL CHEM, V267, P897
  • [19] BRADYKININ-DEGRADING ENZYMES - STRUCTURE, FUNCTION, DISTRIBUTION, AND POTENTIAL ROLES IN CARDIOVASCULAR PHARMACOLOGY
    SKIDGEL, RA
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1992, 20 : S4 - S9
  • [20] WARD PE, 1991, BRADYKININ ANTAGONIS, P147